Michael Ganz, MD
Nephrology · Billings, MTNPI 1356399257
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,910 of the $43,155 with a category attached, or 85.5%. Amgen accounts for 72.9% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $11,538 and has fallen 99.8% since, to $26 in 2025.
Across 96 payments — averaging $449.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$31K
- Genentech USA, Inc.$11K
- Bayer$175
- Travere Therapeutics, Inc.$132
- GSK$130
- AstraZeneca$111
- plus $246 from 7 others
What the payments were for
- Speaking & faculty fees$36,91086%
- Travel & lodging$4,31010%
- Food & beverage$1,9284%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 46 | $31,477 |
| Genentech USA, Inc. | 12 | $10,884 |
| Bayer | 9 | $175 |
| Travere Therapeutics, Inc. | 3 | $132 |
| GSK | 9 | $130 |
| AstraZeneca(2 entities) | 6 | $111 |
| Boehringer Ingelheim | 3 | $62 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Ultragenyx Pharmaceutical Inc. | 2 | $35 |
| ANI Pharmaceuticals, Inc. | 1 | $34 |
| Outset Medical Inc | 1 | $26 |
| Baxter Healthcare | 1 | $24 |
| Biogen | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few nephrology providers in Montanato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $15,705 |
| Sevelamer Carbonate | 88 | $15,328 |
| Nifedipine ErNifedipine | 121 | $3,939 |
| Clonidine | 15 | $3,392 |
| Calcium Acetate | 23 | $1,762 |
| Potassium Citrate ErPotassium Citrate | 15 | $1,442 |
| Metolazone | 74 | $1,372 |
| Hydralazine Hcl | 117 | $1,172 |
| Bumetanide | 54 | $1,120 |
| Gabapentin | 40 | $1,092 |
| Mycophenolate Mofetil | 17 | $1,082 |
| Losartan Potassium | 95 | $1,080 |
| Temazepam | 115 | $941 |
| Amlodipine Besylate | 146 | $914 |
| Potassium Chloride | 52 | $913 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Billings
- Kristen ZackBillings$652
- Jonathan JakubowskiBillings$300
- Ali Riza KoksalBillings$144
- Grace KimBillings$23
- Kendrick TrostelBillings$19
- Ruslan SoldyshevGreat Falls$83K
- Gabor Bodonyi-KovacsKalispell$1K
- Scot BornKalispell$668
- Benjamin LawsonMissoula$471
- Robert ValleauKalispell$260
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.